Its approval by the European Medicines Agency (EMA) in 2015 and the U.S. Food and Drug Administration (FDA) in 2017 highlights the ongoing relevance and expanding therapeutic potential of MAO-B inhibitors in Parkinson’s disease management [2]. Here, MAOB is linked to Parkinson disease.